# A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

> **NCT05021666** · PHASE1 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Placebo
- **DRUG:** PB 718

## Key facts

- **NCT ID:** NCT05021666
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2022-05-18
- **Final completion:** 2022-08-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2022-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021666, "A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05021666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*